AstraZeneca PLC (AZN.L) News Headlines

▮ More

Date

Headline

5/23/2022 7:07:25 AM AstraZeneca Aims To Transform Cancer Care With Practice-changing Data At ASCO 2022

5/23/2022 4:22:54 AM AstraZeneca: EU Approves Covid-19 Vaccine Vaxzevria As Third Dose Booster

5/23/2022 3:54:58 AM AstraZeneca's Covid-19 Vaccine Vaxzevria Gets EU Approval As Third Dose Booster

5/17/2022 1:16:37 AM BenevolentAI Says Achieves Third Milestone In AI-enabled Drug Discovery Collaboration With AZN

5/15/2022 9:28:40 PM AZN : Phase III Trial Shows PT027 Reduces Risk Of Severe Exacerbation By 27% In Asthma Patients

5/5/2022 3:32:46 AM AZN : Phase III Trial Of Farxiga Effective In Treating Heart Failure Regardless Of Ejection Fraction

5/5/2022 3:18:43 AM AZN : Phase III Trial Of Ultomiris Meets Main Goal In Neuromyelitis Optica Spectrum Disorder

5/5/2022 3:04:41 AM FDA Oks AstraZeneca's Enhertu To Treat Unresectable Or Metastatic HER2 Positive Breast Cancer

5/5/2022 2:21:34 AM AstraZeneca: Ultomiris Meets Primary Endpoint In CHAMPION-NMOSD Phase 3 Trial In Neuromyelitis Optica Spectrum Disorder

5/5/2022 2:16:11 AM AstraZeneca: Enhertu Approved In US For Unresectable Or Metastatic HER2-positive Breast Cancer In Adults

5/5/2022 2:15:05 AM AstraZeneca Says Farxiga Meets Primary Endpoint In DELIVER Phase III Trial

5/4/2022 2:32:24 AM AZN : Imfinzi Plus Chemotherapy Granted Priority Review In U.S. For Metastatic Biliary Tract Cancer

5/4/2022 2:12:01 AM AstraZeneca Says Imfinzi Plus Chemotherapy Granted Priority Review In US For Biliary Tract Cancer

4/29/2022 6:43:38 AM AstraZeneca Stock Down On Weak Q1 Profit; Backs FY22 View

4/29/2022 2:38:20 AM AstraZeneca Q1 Core Profit Rises, Revenue Up 60%: Reiterates FY22 Guidance At CER

4/29/2022 2:10:35 AM AstraZeneca Plans For New Strategic R&D Centre And Alexion Headquarters In Cambridge, Massachusetts

4/29/2022 2:06:56 AM AstraZeneca PLC Q1 Reported EPS $0.25; Core EPS $1.89

4/29/2022 1:04:44 AM Innate : First Patient Dosed In Monalizumab Phase 3 Lung Cancer Trial Triggers $50 Mln Payment From AstraZeneca

4/28/2022 3:20:45 AM FDA Oks AstraZeneca's Ultomiris For Treatment Of Adult Patients With Generalised Myasthenia Gravis

4/28/2022 2:19:51 AM AstraZeneca Says Ultomiris Approved In The US For Adults With Generalised Myasthenia Gravis

Astrazeneca Plc (AZN.L)